Weight Loss Stocks - Directory w/ AI Reviews
The obesity treatment market has rapidly become one of the most consequential in pharmaceutical investing, driven by the blockbuster success of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. Eli Lilly and Novo Nordisk are the two dominant players, generating billions in quarterly revenue from drugs that are reshaping treatment of both obesity and type 2 diabetes. Viking Therapeutics and Amgen are among the next-generation challengers developing competing GLP-1 and alternative mechanisms, while downstream beneficiaries like Peloton and WW International are navigating a market that is simultaneously disrupted and expanded by effective medical weight loss.
1
4.8
New
Eli Lilly
LLY
$1,040.00
+0.17%
P/E: 54.7
Eli Lilly has become one of the world's most valuable companies driven by its GLP-1 weight loss and diabetes drugs Mounjaro and Zepbound, leading the obesity treatment revolution.
2
4.7
New
Novo Nordisk
NVO
$49.57
+1.31%
P/E: 2.9
Novo Nordisk is the global leader in GLP-1 weight loss and diabetes treatments with Ozempic and Wegovy, dominating the obesity drug market alongside Eli Lilly.
3
4.2
New
Structure Therapeutics
GPCR
$70.07
-2.73%
Structure Therapeutics is developing oral small molecule GLP-1 drugs that could provide a more convenient alternative to injectable weight loss treatments, offering pipeline-stage obesity drug exposure.
4
3.8
New
Viking Therapeutics
VKTX
$29.00
-4.89%
P/E: 24.2
Viking Therapeutics is developing novel oral GLP-1 therapies for metabolic disorders, offering clinical-stage pipeline exposure to the next generation of weight loss treatments.
5
3.6
New
Amgen
AMGN
$369.19
+0.82%
P/E: 22.0
Amgen is developing MariTide, a promising next-generation obesity drug candidate that could compete in the rapidly growing weight loss therapeutics market alongside Eli Lilly and Novo Nordisk.
6
3.2
New
Lululemon Athletica
LULU
$176.42
+4.06%
P/E: 20.0
Lululemon could benefit from the weight loss drug trend as consumers adopting healthier lifestyles increase spending on premium athletic and wellness apparel.
7
2.8
New
WW International
WW
$23.22
+0.96%
P/E: 2.0
WW International (formerly Weight Watchers) is a global wellness company providing weight management programs through digital tools, coaching, and clinical solutions, adapting to the GLP-1 drug era.
8
2.3
New
Peloton Interactive
PTON
$4.25
+0.47%
P/E: 1.7
Peloton's connected fitness platform and subscription content could benefit from the weight loss drug trend as users seeking active lifestyles increase engagement with at-home fitness.